Sometimes, you don't need too many reasons to invest in a stock, only one strong point is enough to make the investment, and Charles River Laboratories (CRL) is a good example of this.
After a challenging period from 2008 through 2011, share performance of the CROs has rebounded nicely over the last several years, with the momentum continuing thus far in 2014. Big pharma companies are under pressure to cut costs to offset sales lost to patent expiration. So, to reduce cash expenditures, pharma companies are moving toward CROs to outsource R&D models. This provides an excellent opportunity to the CRO industry, which has grown 10.2% to $13.6 billion since 2011. Behind solid quarterly earnings results for 2013
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|